Osteoporosis treatment: the battle to be won
Autor: | João Lindolfo C. Borges |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Pediatrics
medicine.medical_specialty Battle business.industry Endocrinology Diabetes and Metabolism media_common.quotation_subject Gold standard Osteoporosis urologic and male genital diseases medicine.disease RC648-665 Diseases of the endocrine glands. Clinical endocrinology Osteogenesis imperfecta Osteoporosis treatment medicine Humans Medicine business hormones hormone substitutes and hormone antagonists media_common |
Zdroj: | Archives of Endocrinology and Metabolism, Vol 64, Iss 4, Pp 327-328 (2020) Archives of Endocrinology and Metabolism, Volume: 64, Issue: 4, Pages: 327-328, Published: 12 AUG 2020 |
ISSN: | 2359-4292 |
Popis: | Bisphosphonates (BPs) are the pioneer and gold standard drugs for osteoporosis treatment. The development of BPs started decades ago. There are four bisphosphonates in the osteoporosis market: alendronate, risedronate, ibandronate, and zolendronate. Pamidronate, an important BP, is used for the treatment of osteogenesis imperfecta ( ). shows the evolution of BPs discovery and approval for osteoporosis treatment. […] Osteoporosis treatment: the battle to be won |
Databáze: | OpenAIRE |
Externí odkaz: |